Verekitug (UPB-101)
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Key Facts
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company focused on developing verekitug, a first-in-class monoclonal antibody antagonist of the TSLP receptor, for major inflammatory respiratory diseases. The company has completed Phase 2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, with an ongoing Phase 2 trial in chronic obstructive pulmonary disease (COPD). Its strategy is predicated on disrupting a key upstream inflammatory mediator to potentially achieve broader efficacy and a more convenient dosing regimen than existing biologics, aiming to capture significant share in large, underserved markets.
View full company profileAbout Upstream Bio
Upstream Bio is a clinical-stage biotechnology company focused on developing verekitug, a first-in-class monoclonal antibody antagonist of the TSLP receptor, for major inflammatory respiratory diseases. The company has completed Phase 2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, with an ongoing Phase 2 trial in chronic obstructive pulmonary disease (COPD). Its strategy is predicated on disrupting a key upstream inflammatory mediator to potentially achieve broader efficacy and a more convenient dosing regimen than existing biologics, aiming to capture significant share in large, underserved markets.
View full company profileAbout Upstream Bio
Upstream Bio is a clinical-stage biotechnology company focused on developing verekitug, a first-in-class monoclonal antibody antagonist of the TSLP receptor, for major inflammatory respiratory diseases. The company has completed Phase 2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, with an ongoing Phase 2 trial in chronic obstructive pulmonary disease (COPD). Its strategy is predicated on disrupting a key upstream inflammatory mediator to potentially achieve broader efficacy and a more convenient dosing regimen than existing biologics, aiming to capture significant share in large, underserved markets.
View full company profileTherapeutic Areas
Other Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Drugs
| Drug | Company | Phase |
|---|---|---|
| XHANCE (fluticasone propionate) | Paratek Pharmaceuticals | Marketed |